Here's How Artificial Intelligence (AI) Is Driving Profit Growth for These 2 Tech Stocks

The markets reacted positively to President Trump's announcement of a 90-day pause on reciprocal tariffs for most countries, coupled with a base 10% tariff on goods, but automakers like General Motors (GM) were excluded from tariff relief, facing a looming 25% tariff on vehicle imports and parts. GM has been aggressively buying back shares, announcing $16 billion in buybacks from 2023 to 2025, but the new tariffs could force it to reconsider this strategy, as...

XRP (XRP 7.56%) aims to revolutionize financial transactions by tokenizing real-world assets (RWAs), potentially capturing a $19 trillion market by 2033, as reported by Ripple and Boston Consulting Group. Currently, only $600 billion of RWAs are tokenized, presenting an opportunity for significant growth on XRP's platform, which has already facilitated over $1 trillion in asset transactions. However, while XRP is well-positioned, challenges remain due to competition and the uncertain relationship between the volume of tokenized...

SummaryIn a declining market, investors often seek bargains among top performers like American Express, which has dropped nearly 30% but offers a low yield of 1.4%. Instead of chasing unreliable high-yield stocks such as AGNC Investment (down 20%, yielding 16% with a history of dividend cuts), income investors are advised to consider more stable options like UDR (4.2% yield), Toronto-Dominion Bank (5.1% yield), and W.P. Carey (6% yield), which have strong fundamentals and reliable dividend...

In a turbulent stock market, three Motley Fool contributors recommend investing in CRISPR Therapeutics, Summit Therapeutics, and Viking Therapeutics, which they believe could see significant gains by 2030. CRISPR Therapeutics, despite recent struggles, has a promising gene-editing therapy, Casgevy, and a robust pipeline. Summit Therapeutics is poised to challenge established drugs with its ivonescimab, while Viking Therapeutics offers potential through its GLP-1 drug, VK2735, with ongoing clinical trials targeting obesity and metabolic disorders. Full Article

Warren Buffett's Berkshire Hathaway is investing in Nu Holdings, a fintech company addressing the banking needs of a largely unbanked population in Latin America. Despite a recent 37% decline in stock value from its peak, Nu has experienced significant growth, with a 43% revenue increase and a doubling of customers since 2021. The company's strong unit economics and potential for developing customer loyalty suggest an attractive investment opportunity, especially at a forward price-to-earnings ratio of...

Recent market sell-offs present opportunities for investors to buy shares of proven companies at discounted prices, with Shopify, RH, and Roblox among those down 51% to 77% from their peaks. Shopify, the largest U.S. e-commerce software company, is seeing profitable growth and expanding its offerings, while RH, a high-end home furnishings retailer, has been affected by tariffs and a weak housing market but shows resilience with strong cash flow prospects. Both stocks, despite current risks,...